Group 1 - The core point of the article is that Dian Diagnostics reported a total of 45,695 common stock shareholders as of September 30, 2025 [2]

Market Overview - The Shanghai Composite Index closed at 3876.74 points, above the six-month moving average, with a change of 0.17% [1] - The total trading volume of A-shares reached 1,352.099 billion yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 151 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Xingchen Technology (21.97%) - Lude Medical (14.72%) - Suli Co., Ltd. (7.17%) [1] Stocks with Smaller Deviation Rates - Stocks with smaller deviation rates that have just crossed the six-month moving average include: - Huailong Co., Ltd. - Shihong Zhaoye - China Construction Bank [1] Detailed Stock Performance - The following stocks showed notable performance: - Xingchen Technology: +30.00% with a turnover rate of 37.59% and a latest price of 26.48 yuan [1] - Lude Medical: +18.92% with a turnover rate of 37.56% and a latest price of 12.07 yuan [1] - Suli Co., Ltd.: +9.99% with a turnover rate of 7.67% and a latest price of 20.36 yuan [1]

Group 1 - The core viewpoint of the news is that Dian Diagnostics has seen a stock price increase of 5.09%, reaching 15.91 yuan per share, with a trading volume of 1.67 billion yuan and a market capitalization of 99.43 billion yuan as of the report date [1] - Dian Diagnostics, established on September 5, 2001, and listed on July 19, 2011, provides medical diagnostic services primarily to various healthcare institutions, with its main business revenue composition being 65.34% from channel products and 34.66% from diagnostic services [1] Group 2 - Among the top circulating shareholders of Dian Diagnostics, a fund under Yongying Fund ranks first, while the Medical Device ETF (159883) entered the top shareholders in the third quarter, holding 3.0875 million shares, which is 0.62% of the circulating shares [2] - The Medical Device ETF (159883) was established on April 22, 2021, with a current scale of 4.73 billion yuan, showing a year-to-date return of 1.98% and a one-year loss of 1.18% [2]

Group 1 - The core viewpoint of the article highlights that the precision medicine sector experienced a 1.16% increase on December 17, with Di'an Diagnostics leading the gains [1] - The Shanghai Composite Index closed at 3870.28, up by 1.19%, while the Shenzhen Component Index closed at 13224.51, up by 2.4% [1] - The article provides a summary of the fund flow in the precision medicine sector, indicating a net outflow of 101 million yuan from main funds and 164 million yuan from speculative funds, while retail investors contributed a net inflow of 265 million yuan [1] Group 2 - The article includes a table detailing the individual stock performance within the precision medicine sector, although specific stock data is not provided in the text [1] - The information is compiled from public sources and generated by AI algorithms, indicating a reliance on data analysis for insights [1]

Group 1 - The core announcement from the company is the approval of multiple resolutions by the fifth board of directors' seventeenth meeting, including the cancellation of the supervisory board and amendments to certain corporate governance systems [2] - The company has also proposed to hold the first extraordinary general meeting of shareholders in 2025 [2]

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (港币) closed at 4287.1 points, down 0.23%, with a trading volume of 7.011 billion yuan and a turnover rate of 0.72% [1] Group 1: Index Performance - On the day, 18 constituent stocks rose, with Blue Sail Medical leading with a 10.0% increase, while 36 stocks declined, with Yimai Sunshine leading the decline at 3.83% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 115 million yuan, while retail investors saw a net inflow of 181 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Yimai Sunshine (hk02522) with a market cap of 3.43 billion yuan and a price drop of 3.83% [1] - Weikang Medical (hk00853) with a market cap of 17.4 billion yuan and a price drop of 3.38% [1] - Weikang Robotics (hk02252) with a market cap of 19.21 billion yuan and a price drop of 2.84% [1] - Wu Hai Biotechnology (hk06826) with a market cap of 5.46 billion yuan and a price drop of 2.27% [1] - Dian Diagnostics (sz300244) with a market cap of 9.19 billion yuan and a price drop of 2.13% [1] - Ruimaite (sz301367) with a market cap of 7.59 billion yuan and a price drop of 2.08% [1] - Tuya Holdings (hk01099) with a market cap of 56.54 billion yuan and a price drop of 1.96% [1] - Yidu Technology (hk02158) with a market cap of 4.83 billion yuan and a price drop of 1.96% [1] - Xintai Medical (hk02291) with a market cap of 5.23 billion yuan and a price drop of 1.83% [1] - Chunli Medical (hk01858) with a market cap of 5.26 billion yuan and a price drop of 1.76% [1]

第一章 总 则 第一条 为建立、完善迪安诊断技术集团股份有限公司（以下简称"公司"）高级管 理人员的业绩考核与评价体系，制订科学、有效的薪酬管理制度，实施公司的人才开发与 利用战略，董事会决定下设公司薪酬与考核委员会，作为制订和管理公司高级人力资源薪 酬方案，评估高级管理人员业绩指标的专门机构。 薪酬与考核委员会工作条例 薪酬与考核委员会工作条例 （2025 年 12 月） 第二条 为规范、高效地开展工作，公司董事会根据《公司法》《上市公司治理 准则》《上市公司独立董事管理办法》《公司章程》等有关规定，制订本工作条例。 第三条 薪酬与考核委员会所作决议，必须遵守《公司章程》、本工作条例及其 他有关法律、法规的规定；薪酬与考核委员会决议内容违反《公司章程》、本工作条例及 其他有关法律、法规的规定，该项决议无效；薪酬与考核委员会决策程序违反《公司章程》、 本工作条例及其他有关法律、法规的规定的，自该决议作出之日起 60 日内，有关利害关 系人可向公司董事会提出撤销该项决议。 第二章 人员组成 第四条 薪酬与考核委员会由三人组成，其中独立董事应当过半数并担任召集人， 薪酬与考核委员会委员由公司董事会选举产生。 第五 ...

董事会议事规则 董事会议事规则 （2025 年 12 月） 第一章 总 则 第一条 为规范迪安诊断技术集团股份有限公司（以下简称"公司"或者"上市公司"） 董事会议事和决策行为，保障董事会的高效运作和科学决策，根据《中华人民共和国公司 法》《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称《" 自律监管指引》"） 等有关法律、法规、规范性文件及《迪安诊断技术集团股份有限公司章程》（以下简称"《公 司章程》"）等的规定，特制定本规则。 第二章 董 事 第二条 有下列情形之一者，不得被提名担任公司的董事： （一） 无民事行为能力或者限制民事行为能力； （二） 因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序，被判 处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾5年，被宣告缓刑的，自缓刑考验期 满之日起未逾二年； （三） 担任破产清算的公司、企业的董事或者厂长、经理，对该公司、企业的破产 负有个人责任的，自该公司、企业破产清算完结之日起未逾3年； （四） 担任因违法被吊销营业执照、责令关闭的公司、企业的法定代表人 ...

（2025 年 12 月） 第一章 总则 第一条 为进一步完善迪安诊断技术集团股份有限公司（以下简称"公司"）的法人治 理结构，促进公司规范运作，明确独立董事的职责，强化对内部董事及经理层的约束和 监督机制，保障全体股东特别是中小股东的合法权益不受损害，根据《中华人民共和国 公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券 法》"）《上市公司独立董事管理办法》（以下简称"《管理办法》"）《上市公司治理准 则》《深圳证券交易所创业板股票上市规则》等法律、法规、规范性文件以及《迪安诊 断技术集团股份有限公司章程》（以下简称"《公司章程》" ）等相关规定，结合公司的 实际情况，特制定本制度。 第二条 独立董事是指不在公司担任除独立董事外的任何其他职务，并与公司及其 主要股东、实际控制人不存在直接或间接的利害关系，或者其他可能影响其进行独立客 观判断的关系的董事。 独立董事制度 独立董事制度 第三条 独立董事对公司及全体股东负有忠实与勤勉的义务，应当按照法律、行政 法规、中国证券监督管理委员会（以下简称"中国证监会"）规定、证券交易所业务规则 和《公司章程》的要求，认真履行职责，在董事会中 ...

第一条 为保证迪安诊断技术集团股份有限公司（以下简称"公司"）与关联人之间 的关联交易符合公平、公正、公开的原则，确保公司的关联交易行为不损害公司和非关联 股东的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《企业会计 准则——关联方关系及其交易的披露》《深圳证劵交易所创业板股票上市规则》（以下简 称：上市规则）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律、法规、规范性文件及《迪安诊断技术集团股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，结合公司实际情况，制订本制度。 第二条 公司与关联人之间的关联交易除遵守有关法律、法规、规范性文件及《公司 章程》的规定外，还需遵守本制度的有关规定。 第三条 公司及其关联方不得利用关联交易输送利益或者调节利润，不得以任何方式 隐瞒关联关系。公司关联交易行为应当合法合规，不得通过将关联交易非关联化规避相关 审议程序和信息披露义务。相关交易不得存在导致或者可能导致公司出现被控股股东、实 际控制人及其他关联人非经营性资金占用、为关联人违规提供担保或者其他被关联人侵占 利益的情形。。 第四条 关联交易活动应遵 ...